In the evolving field of drug delivery, polymer-based technologies have transformed the way medications are administered for prolonged efficacy. One such innovation is Sublocade, a long-acting injectable formulation of Buprenorphine, used for opioid dependence treatment. A crucial component enabling its sustained-release mechanism is Poly (lactic-co-glycolic acid).
Sublocade and Its Active Ingredient: Buprenorphine
Sublocade is an extended-release Buprenorphineinjection designed for once-monthly subcutaneous administration. Buprenorphine, a partial opioid agonist, helps manage opioid dependence by reducing withdrawal symptoms and cravings without producing the same euphoric effects as full opioids. The drug’s success relies on its ability to maintain therapeutic levels in the bloodstream over extended periods—this is where PLGA plays a key role.
The Role of PLGA in Sublocade
PLGA is a biodegradable and biocompatible polymer widely used in pharmaceutical applications, particularly in long-acting injectable drugs like Sublocade. The specific PLGA used in this formulation is designed tocontrol the release of Buprenorphine over a month, ensuring a steady drug concentration that eliminates the need for daily dosing.
Key Functions of PLGA in Sublocade:
-
Sustained Release: PLGA enables a controlled and predictable drug release by gradually degrading into lactic and glycolic acid, which are naturally metabolized by the body.
-
Biodegradability: Unlike traditional drug carriers, PLGA does not require surgical removal; it completely dissolves in the body.
-
Enhanced Patient Compliance: The once-monthly administration reduces the burden of daily medication adherence, improving treatment outcomes.
-
Minimized Side Effects: Controlled drug release helps maintain stable blood levels, reducing fluctuations that can lead to withdrawal symptoms or overdose risks.
Nomisma Healthcare: Your Trusted Manufacturer of PLGA
PLGA is not just a component of Sublocade; it is a critical material used in variousdrug delivery systems, implants, and biomedical applications. Nomisma Healthcare Pvt. Ltd. specializes in the manufacturing of high-purity PLGA, ensuring that pharmaceutical companies worldwide have access to this essential polymer.
At Nomisma, we manufacture PLGA with various lactide-to-glycolide ratios, molecular weights, and end-group modifications to meet specific drug release requirements. Our PLGA is used in:
-
Injectable drug depots (e.g., long-acting release formulations like Sublocade)
-
Microparticles and nanoparticles for drug targeting
-
Implants and scaffolds for regenerative medicine
-
Medical devices for sustained therapeutic effects
Why Choose Nomisma for PLGA?
-
High Purity & Quality Assurance: Our PLGA meets stringent pharmaceutical standards, ensuring consistency and safety.
-
Customizable Solutions: We offer tailored PLGA compositions to suit specific drug delivery needs.
-
Global Reach: Supplying PLGA to pharmaceutical industries worldwide, supporting innovations in drug formulation.
-
Regulatory Compliance: Our products align with international regulatory requirements for pharmaceutical-grade biopolymers.
Shaping the Future of Drug Delivery with PLGA
With the rising demand for sustained-release pharmaceuticals, PLGA has become an indispensable material in modern medicine.Nomisma Healthcare takes pride in being a key player in this field, providing high-quality PLGA that enables pharmaceutical breakthroughs like Sublocade and beyond.
For inquiries and orders, visit www.nomismahealthcare.com and explore our range of biopolymers that power the next generation of drug delivery solutions.
Nomisma Healthcare – Innovating with Biopolymers for a Healthier Future.